Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- pain (anterior uveitis)
- decreased vision
- synechiae
- flare
- keratic precipitates
Other diagnostic factors
- tearing
- photophobia
- floaters
- eye redness without discharge
- constricted or non-reactive pupil
- decreased intra-ocular pressure
- retinal exudates and oedema, optic nerve oedema
- retinal vascular sheathing
- macular oedema
- optic disc swelling
- retinal haemorrhages
- ciliary flush
- corneal oedema
- cataract
Risk factors
- inflammatory diseases of the joints, bowel, or skin
- human leukocyte antigen (HLA)-B27 positive
- ocular trauma
- age 30 to 40 years
Diagnostic investigations
Investigations to consider
- FBC
- erythrocyte sedimentation rate
- CRP
- fluorescent treponemal antibody (FTA-ABS), Venereal Disease Research Laboratory (VDRL), and rapid plasma reagin (RPR)
- serum ACE
- antinuclear antibodies
- HLA-B27
- Lyme titre
- purified protein derivative (PPD) skin test
- cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA)
- perinuclear antineutrophil cytoplasmic antibodies (p-ANCA)
- antidouble-stranded DNA antibody (anti-dsDNA)
- rheumatoid factor
- anticyclic citrullinated peptide (anti-CCP) antibodies
- Bartonella henselae titre
- toxoplasma serological titre
- other HLA antigens
- chemistry screen
- CXR
- polymerase chain reaction (PCR)
Treatment algorithm
Contributors
Authors
John J. Huang, MD
President
Connecticut Uveitis Foundation
Associate Clinical Professor
Yale University
New Haven
New England Retina Associates
Hamden
CT
Disclosures
JJH declares that he has no competing interests.
Maxwell Elia, MD
Uveitis and Retina Specialist
Medical Eye Center of New Hampshire
Manchester
NH
Disclosures
ME declares that he has no competing interests.
Acknowledgements
Dr John J. Huang and Dr Maxwell Elia would like to gratefully acknowledge Dr Richard Gale, Dr Zsolt Varga, Dr Victor L. Perez, and Dr Carlos A. Medina, the previous contributors to this topic.
Disclosures
RG, ZV, VLP, and CAM declare that they have no competing interests.
Peer reviewers
Jessica Ackert, MD
Assistant Professor
Ophthalmology
Mount Sinai Hospital
New York
NY
Disclosures
JA declares that she has no competing interests.
Anthony J. Hall, MD, FRANZCO
Director of Ophthalmology
Alfred Hospital
Melbourne
Australia
Disclosures
AJH has been reimbursed by Novartis, the manufacturer of Lucentis, for lecture fees. AJH's employer, the Alfred Hospital, has received research funding from Novartis, the manufacturer of Lucentis, and from Bayer, the manufacturer of Eylea.
Daniel A. Johnson, MD
Chairman
Department of Ophthalmology
The University of Texas Health Science Center at San Antonio
San Antonio
TX
Disclosures
DAJ declares that he has no competing interests.
References
Key articles
Deschenes J, Murray PI, Rao NA, et al; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2. Abstract
Jabs DA, Nussenblatt RD, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Abstract
Kempen JH, Altaweel MM, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available here.
Use of this content is subject to our disclaimer